Vendor Intelligence Report: Guangzhou Jeep Biotechnology JEEP

Executive summary

JEEP is a product-specific file, not a simple good-vendor/bad-vendor call. Across 30 Finnrick lab tests, the supplied headline record is 28 pass / 1 fail, for a 93% overall pass rate. Retatrutide and GHK-Cu are the strongest signals in the tested catalog; Tirzepatide still mostly clears identity and purity, but carries the weakest buyer read because its analytical record sits beside a separate T30 safety event. Ratings also compress under stricter grading, so dose-accuracy-focused buyers need the full methodology views.

The high-severity issue is narrow but serious: a Tirzepatide 30mg orange-cap batch was tied in public forum records to repeated elevated endotoxin results, adverse-reaction reports, and traceability problems where cap color became more informative than the formal batch number. Later low-endotoxin T30/T60 results point toward a batch- or presentation-specific event rather than a proven catalog-wide failure, but they do not repair the lot-control weakness.

Operationally, the public trail anchors JEEP to a GLP-1 Forum sponsor presence and sales identities rather than to an independently verified Chinese registry record, factory, legal representative, or upstream manufacturer. Current promotions confirm US warehouse inventory with separate pricing and a lower MOQ, but the physical warehouse and fulfillment partner remain undisclosed.

Brand-confusion risk is active. The report separates likely impersonator infrastructure from the real forum vendor, documenting one JEEP-branded domain flagged for suspected phishing, another evolved into a full storefront, spoofed handles, and Reddit-described deposit/insurance scam patterns. The public X/web affiliate sweep was quiet, but private-platform coverage remains outside scope.

Inside the full report:

• Per-product pass/fail read, rating trajectories, and methodology-divergence charts for all 3 tested products
• Timeline and evidence matrix for the Tirzepatide 30mg orange-cap endotoxin incident
• Corporate-identity and registry-source audit covering China registry access gaps and unsupported manufacturer attribution
• US warehouse promotion captures, China-warehouse terms, and current contact-channel analysis
• Per-domain impersonator forensics covering phishing warnings, storefront evolution, spoofed handles, and scam reports
• Material risk matrix separating product safety, traceability, sterility assurance, fraud, and corporate-opacity risks

Risk assessment

• Tirzepatide 30mg endotoxin contamination risk — high: April 2026 community testing reports for JEEP Tirzepatide 30mg orange-cap JP20250616 listed 1,350, 1,360, and 2,306 EU/vial, with anecdotal rash and elevated-heart-rate reports.
• Batch-traceability risk — high: Tirzepatide 30mg vials with materially different endotoxin findings reportedly shared batch JP20250616, leaving cap color rather than batch number as the practical distinction.
• Sterility and endotoxin assurance risk — high: JEEP's own post-incident posture guarantees purity and fill, but field notes state it disclaimed Lilly-comparable endotoxin assurance for injectable products.
• Copycat and brand-confusion fraud risk — high: jeepmolly.com operates as a full impersonator storefront, jeeppeptides.com shows a phishing warning, and Reddit reports document security-deposit scams against confused buyers.
• Corporate-identity opacity risk — medium: No verifiable Chinese registry entry, registration number, physical address, legal representative, or upstream manufacturer was confirmed from accessible public sources.